The short version of pentapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-02. Anything still debated is marked as such rather than presented as settled.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Tanzi, RE; Petrukhin, K; Chernov, I; Pellequer, JL; Wasco, W; Ross, B; Romano, DM; Brzustowicz, LM; Devoto, M; Peppercorn, J; Bush, AI; Sternlieb, I; Pirastu, M; Gusella, JF; Evgrafov, O; Penchaszadeh, GK; Honig, B; Edelman, IS; Soares, MB; Scheinberg, IH; Gilliam, TC (1993). "Identification of the Wilson's disease gene: A copper transporting ATPase with homology to the Menke's disease gene". Nature Genetics. 5 (4): 344–350. Bibcode:1993NaGen...5..344T. doi:10.1038/ng1293-344. PMID 8298641. S2CID 610188. Levy-Lahad, E; Wasco, W; Poorkaj, P; Romano, DM; Oshima Jm, Pettingell WH; Yu, C; Jondro, PD; Schmidt, SD; Wang, K; Crowley, AC; Fu, Y-H; Guenette, SY; Galas, D; Nemens, E; Wijsman, EM; Bird, TD; Schellenberg, GD; Tanzi, RE (1995). "Candidate gene for the chromosome 1 familial Alzheimer's disease locus". Science. 269 (5226): 973–977. Bibcode:1995Sci...269..973L. doi:10.1126/science.7638622. PMID 7638622. S2CID 27296868. Bertram, L; Blacker, D; Mullin, K; Keeney, D; Jones, J; Basu, S; Yhu, S; McInnis, M; Go, R; Vekrellis, K; Selkoe, D; Saunders, A; Tanzi, RE (2000). "Evidence for genetic linkage of Alzheimer's disease to chromosome 10q". Science. 290 (5500): 2302–2303. Bibcode:2000Sci...290.2302B. doi:10.1126/science.290.5500.2302. PMID 11125142. Bertram, L; Hiltunen, M; Parkinson, M; Ingelsson, M; Lange, C; Ramasamy, K; Mullin, K; Menon, R; Sampson, AJ; Hsiao, MY; Elliott, KJ; Moscarillo, T; Hyman, BT; Wagner, SL; Becker, KD; Blacker, D; Tanzi, RE (2005). "Family-based association between Alzheimer's disease and variants in UBQLN1". N. Engl. J. Med. 352 (9): 884–894.
Until the time of Napoleon, European states employed relatively small armies, made up of both national soldiers and mercenaries. These regulars were highly drilled, professional soldiers. Ancien Régime armies could only deploy small field armies due to rudimentary staffs and comprehensive yet cumbersome logistics. Military innovators in the mid-18th century began to recognise the potential of an entire nation at war: a "nation in arms". The scale of warfare dramatically enlarged during the Revolutionary and subsequent Napoleonic Wars. During Europe's major pre-revolutionary war, the Seven Years' War of 1756–1763, few armies ever numbered more than 200,000 with field forces often numbering less than 30,000. The French innovations of separate corps (allowing a single commander to efficiently command more than the traditional command span of 30,000 men) and living off the land (which allowed field armies to deploy more men without requiring an equal increase in supply arrangements such as depots and supply trains) allowed the French republic to field much larger armies than their opponents. Napoleon ensured during the time of the French republic that separate French field armies operated as a single army under his control, often allowing him to substantially outnumber his opponents. This forced his continental opponents to also increase the size of their armies, moving away from the traditional small, well-drilled Ancien Régime armies of the 18th century to mass conscript armies.
Corticotropin-like intermediate [lobe] peptide (CLIP), also known as adrenocorticotropic hormone fragment 18-39 (ACTH(18-39)), is a naturally occurring, endogenous neuropeptide with a docosapeptide structure and the amino acid sequence Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe. CLIP is generated as a proteolyic cleavage product of adrenocorticotropic hormone (ACTH), which in turn is a cleavage product of proopiomelanocortin (POMC). Its physiological role has been investigated in various tissues, specifically in the central nervous system. It has been suggested to function as an insulin secretagogue in the pancreas.
=== European Union === In 2000, the European Union (EU) enacted similar legislation, Regulation(EC) No 141/2000, which refers to drugs developed to treat rare diseases to as "orphan medicinal products". The EU's definition of an orphan condition is broader than that of the US, in that it also covers some tropical diseases that are primarily found in developing nations. Orphan drug status granted by the European Commission gives marketing exclusivity in the EU for 10 years after approval. The EU's legislation is administered by the Committee on Orphan Medicinal Products of the European Medicines Agency (EMA). In late 2007 the FDA and EMA agreed to use a common application process for both agencies to make it easier for manufacturers to apply for orphan drug status but, while continuing two separate approval processes.
Dysregulation of O-GlcNAc is associated with cancer cell proliferation and tumor growth. O-GlcNAcylation of the glycolytic enzyme PFK1 at S529 has been found to inhibit PFK1 enzymatic activity, reducing glycolytic flux and redirecting glucose towards the pentose phosphate pathway. Structural modeling and biochemical experiments suggested that O-GlcNAc at S529 would inhibit PFK1 allosteric activation by fructose 2,6-bisphosphate and oligomerization into active forms. In a mouse model, mice injected with cells expressing PFK1 S529A mutant showed lower tumor growth than mice injected with cells expressing PFK1 wild-type. Additionally, OGT overexpression enhanced tumor growth in the latter system but had no significant effect on the system with mutant PFK1. Hypoxia induces PFK1 S529 O-GlcNAc and increases flux through the pentose phosphate pathway to generate more NADPH, which maintains glutathione levels and detoxifies reactive oxygen species, imparting a growth advantage to cancer cells. PFK1 was found to be glycosylated in human breast and lung tumor tissues. OGT has also been reported to positively regulate HIF-1α. HIF-1α is normally degraded under normoxic conditions by prolyl hydroxylases that utilize α-ketoglutarate as a co-substrate. OGT suppresses α-ketoglutarate levels, protecting HIF-1α from proteasomal degradation by pVHL and promoting aerobic glycolysis.
Sources: en.wikipedia.org
=== Adverse effects === There have been several reports and small case series of acute liver injury with jaundice arising 1 to 3 months after starting herbal or dietary supplements containing S. baicalensis.
=== Clinical trials === Phase II clinical trials are in progress for treatment of endometrial cancer, diffuse large B-cell lymphoma, cholangiocarcinoma, and non-Hodgkin lymphoma. Copanlisib in combination with R-CHOP or R-B (rituximab and bendamustine) is in a phase III trial for relapsed indolent non-Hodgkin lymphoma (NHL). Two separate phase III trials are investigating the use of copanlisib in combination with rituximab for indolent NHL and the other using copanlisib alone in cases of rituximab-refractory indolent NHL. In a preclinical study, copanlisib was effective in inhibiting HER2+ breast cancer cells with acquired resistance to the HER2-inhibitors trastuzumab and/or lapatinib. This effect was increased when copanlisib was administered along with the aforementioned HER2-inhibitors. Consequently, treatments of copanlisib with trastuzumab are being clinically trialled in HER2-positive breast cancer patients.
=== Setting === BioShock takes place in Rapture, an underwater city built in the 1940s by business magnate Andrew Ryan, who wanted to create a utopia for society's elite to flourish outside of government control. To protect and isolate Rapture, Ryan bans contact with the surface world. As Rapture flourished, wealth disparities grew, and con man Frank Fontaine used his influence over the disenfranchised working class to establish illegal enterprises and obtain power—enough to rival Ryan. With doctors Brigid Tenenbaum and Yi Suchong, Fontaine created his own company dedicated to researching plasmids and gene tonics. The scientists discovered that sea slugs could produce a substance called ADAM that grants superhuman powers. As ADAM became addictive and demand skyrocketed, Fontaine secretly mass-produced ADAM through slugs implanted in the stomachs of orphaned girls, nicknamed "Little Sisters". Fontaine was killed in a shootout with police, and Ryan took the opportunity to seize his assets, including control of the Little Sisters. In the months that followed, a man amongst the poor named Atlas rose up and began a violent revolution against Ryan, with both sides using plasmid-enhanced humans (known as "Splicers") to wage war on one another. To protect the Little Sisters, Ryan created the "Big Daddies": genetically enhanced humans surgically grafted into gigantic lumbering diving suits designed to escort the sisters as they scavenged ADAM from dead bodies. Tensions came to a head on New Year's Eve of 1958 when Atlas ordered an all-out assault on Ryan and his supporters.
=== Preface === The processing of different materials is determined by the origin of their species and substrate. While vegetable and fruit biomass-based textiles are formed into sheets, biotextiles made from proteins or bacterial cellulose are commonly drawn out during an extrusion and spun into a stronger thread. By cultivating plant and bacterial species on a determined substrate, it is possible to grow materials by harnessing their ability to digest and transform cellulose into natural composites. This process involves collecting them into proper scaffolds and executing physical and chemical treatment, so that these sheets of biomass visually resemble leather and exhibit comparable material and tactile properties. The processing of protein based textiles involves a variety of spinning techniques based on the type and quality that needs to be achieved.
==== Specialized soy sauces and seasonings ==== Since the 2000s, dozens of soy sauces specifically designed for TKG have been marketed by various companies in Japan. These are typically less salty than regular soy sauce and often contain dashi (like kombu or katsuobushi extract) and mirin (sweet rice wine) to complement the egg and rice flavour. Notable examples include:
Sources: en.wikipedia.org
====== Cytokines ====== Sendai virus can induce the production of many cytokines that enhance cellular immune responses. Some evidence that demonstrates that SeV activates the transcription factor NF-κB and this activation helps in protection against SeV infection. SeV can stimulate the production of macrophage inflammatory protein-1α (MIB-1α) and –β (MIB-1β), RANTES (CCL5), tumor necrosis factor-alpha (TNF-alpha), tumor necrosis factor-beta (TNF-beta), interleukin-6 (IL-6 ), interleukin-8 (IL-8), interleukin-1 alpha (IL1A), interleukin-1 beta (IL1B), platelet-derived growth factor (PDGF-AB) and small concentrations of interleukin-2 (IL2) and GM-CSF. Sendai virus can trigger production of interleukin 12 (IL12) and interleukin 23 (IL23) in human macrophages. Even plasmids that deliver the F-coding gene of SeV to tumor cells in model animals trigger the production of RANTES (CCL5) in tumor-infiltrated T-lymphocytes. SeV induces the production of B cell-activating factor by monocytes and by some other cells. Heat-inactivated SeV virus induces the production of IL-10 and IL-6 cytokines by dendritic cells (DC). Most likely, F protein is responsible for this induction because reconstituted liposomes containing F protein can stimulate IL-6 production by DC. The production of IL-6 in response to SeV infection is restricted to conventional dendritic cells (DCs]) subsets, such as CD4+ and double negative (dnDC).
Anatomical pathology (Commonwealth) or anatomic pathology (United States) is a medical specialty that is concerned with the diagnosis of disease based on the gross, microscopic, chemical, immunologic and molecular examination of organs, tissues, and whole bodies (as in a general examination or an autopsy). Anatomical pathology is itself divided into subfields, the main divisions being surgical pathology, cytopathology, and forensic pathology. Anatomical pathology is one of two main divisions of the medical practice of pathology, the other being clinical pathology, the diagnosis of disease through the laboratory analysis of bodily fluids and tissues. Sometimes, pathologists practice both anatomical and clinical pathology, a combination known as general pathology.
The goal of protein design is to find a protein sequence that will fold to a target structure. A protein design algorithm must, thus, search all the conformations of each sequence, with respect to the target fold, and rank sequences according to the lowest-energy conformation of each one, as determined by the protein design energy function. Thus, a typical input to the protein design algorithm is the target fold, the sequence space, the structural flexibility, and the energy function, while the output is one or more sequences that are predicted to fold stably to the target structure. The number of candidate protein sequences, however, grows exponentially with the number of protein residues; for example, there are 20100 protein sequences of length 100. Furthermore, even if amino acid side-chain conformations are limited to a few rotamers (see Structural flexibility), this results in an exponential number of conformations for each sequence. Thus, in our 100 residue protein, and assuming that each amino acid has exactly 10 rotamers, a search algorithm that searches this space will have to search over 200100 protein conformations. The most common energy functions can be decomposed into pairwise terms between rotamers and amino acid types, which casts the problem as a combinatorial one, and powerful optimization algorithms can be used to solve it. In those cases, the total energy of each conformation belonging to each sequence can be formulated as a sum of individual and pairwise terms between residue positions.
Repair may be done by open surgery or by laparoscopic surgery. Open surgery has the benefit of possibly being done under local anesthesia rather than general anesthesia. Laparoscopic surgery generally has less pain following the procedure. In 2015, inguinal, femoral, and abdominal hernias affected about 18.5 million people. About 27% of males and 3% of females develop a groin hernia at some time in their life. Groin hernias occur most often before the age of one and after the age of fifty. Globally, inguinal, femoral, and abdominal hernias resulted in 60,000 deaths in 2015 and 55,000 in 1990.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.